HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?

Hologic (HOLX) is discontinuing its low-margin Fluoroscan InSight FD product by September 30, 2025, a strategic decision not expected to significantly impact overall growth, though it will temper 2026 Skeletal revenues. This move follows a robust Q3, where Skeletal Health sales surged 62.1% driven by Horizon DXA systems, prompting the company to narrow its FY2025 revenue guidance to $4.081-$4.091 billion. Despite mixed analyst estimates, HOLX shares have outperformed the industry, trading at a forward 12-month P/E of 15.10x, significantly below the industry average.

Analysis

Hologic is executing a strategic portfolio refinement by discontinuing its low-margin Fluoroscan InSight FD product, a move not expected to materially impact overall growth. This decision is contextualized by a period of significant strength, particularly within its Skeletal Health division, which reported a 62.1% sales jump in Q3 fiscal 2025 driven by the accelerated ramp-up of its Horizon DXA systems. This robust performance has led management to tighten its 2025 revenue guidance to a range of $4.081-$4.091 billion, supported by anticipated strength across its Diagnostics, Surgical, and rebounding Breast Health segments in the fourth quarter. Despite this positive momentum and stock outperformance over the past six months (+11.2% versus the industry's -9.4% decline), the company's valuation remains compelling; HOLX trades at a forward P/E of 15.10x, a notable discount to the industry average of 27.17x. However, management anticipates Skeletal Health revenues will moderate in fiscal 2026 as pent-up demand is met, and analyst estimates for future earnings show a mixed trend, introducing a degree of uncertainty beyond the current fiscal year.

Key Decisions for Investors

• Given Hologic's strong operational performance and a forward P/E of 15.10x, which is well below the industry average of 27.17x, investors may see the current valuation as an attractive entry or accumulation point.
• The discontinuation of the Fluoroscan product should be interpreted as a positive margin-enhancement strategy rather than a growth headwind, shifting focus to core drivers like the Horizon DXA systems and the robust outlook for the Surgical and Diagnostics divisions.
• Investors should monitor for signs of moderation in Skeletal Health sales into fiscal 2026 and pay close attention to upcoming earnings reports for any shift in the currently mixed analyst estimates for future fiscal years.